Prot #22-0384: A Phase II Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib in Recurrent Platinum Sensitive Ovarian, Peritoneal, and Fallopian Tube Cancer

Project: Research project

Project Details

StatusActive
Effective start/end date2/1/24 → 7/31/28

Funding

  • University of Colorado Denver (FY24.984.001 // Prot #22-0384)
  • ImmunoGen, Inc. (FY24.984.001 // Prot #22-0384)